- Q4-2022 revenue guidance raised to a record $12.5M - $13.0M
- Fiscal 2022 revenue guidance increased to a record
$27.5M - $28.0M
MONTREAL, Nov. 15,
2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH)
(OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company")
a Canadian pharmaceutical company, today announced that it has
raised revenue guidance for its fourth quarter of 2022 to
$12.5 - $13.0
million, an increase of 14% to 18% over previously issued
guidance of $11 million. The Company
is also increasing its fiscal 2022 revenue guidance to $27.5 – 28.0 million, a forecasted increase
exceeding 100% compared to fiscal 2021 revenues of $13.6 million.
The quarterly and yearly revenue increases result from the
continued growth of the two innovative asthma therapies Enerzair®
Breezhaler® and Atectura® Breezhaler® and the low molecular weight
heparin biosimilar REDESCA™, as well as the additional
revenues generated in the fourth quarter by the recently added
ophthalmology products XIIDRA®, SIMBRINZA®, and the epinephrine
auto-injector ALLERJECT®.
"Our lead products have delivered the strong growth we
forecasted for 2022. With a first full year of commercial
activities for Enerzair and Atectura now completed, both
products are generating strong sequential quarterly increases
in the number of total prescribers, total prescriptions and
revenues", said Steve Saviuk, CEO.
"The recent addition of our ophthalmic and severe allergy products
in early August materially impacted our fourth quarter and we
expect them to significantly contribute to our overall 2023
revenues as well".
About Valeo Pharma Inc.
Valeo Pharma is a fast growing pharmaceutical company dedicated
to the commercialization of innovative prescription products in
Canada with a focus on
Respirology/Allergy, Ophthalmology and Specialty Products.
Headquartered in Kirkland, Quebec,
Valeo Pharma has the full capability and complete infrastructure to
register and properly manage its growing product portfolio through
all stages of commercialization. For more information, please visit
www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.